Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALAnerv is a multi-ingredient dietary supplement developed by Alfasigma (formerly Alfa Wassermann) specifically formulated to support the nervous system and manage oxidative stress. The product is primarily indicated for patients with peripheral neuropathies, including diabetic neuropathy and nerve compression syndromes such as carpal tunnel syndrome and sciatica. Its core component is **alpha-lipoic acid (ALA)**, a potent antioxidant that functions in both aqueous and lipid environments to neutralize free radicals and regenerate other antioxidants like Vitamin E. The formulation also includes **gamma-linolenic acid (GLA)**, an essential fatty acid that supports nerve cell membrane integrity and microcirculation. Additionally, ALAnerv contains a complex of B-group vitamins (B1, B2, B5, B6) to facilitate neuronal energy metabolism, alongside Vitamin E and selenium for enhanced antioxidant protection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ALAnerv.